| Literature DB >> 27881127 |
Edith Poku1, Rosie Duncan2, Anju Keetharuth2, Munira Essat2, Patrick Phillips2, Helen Buckley Woods2, Simon Palfreyman3, Georgina Jones4, Eva Kaltenthaler2, Jonathan Michaels2.
Abstract
BACKGROUND: Peripheral arterial disease (PAD) is generally associated with considerable morbidity and reduced quality of life. Patient-reported outcome measures (PROMs) provide important information about the burden of disease and impact of treatment in affected patients.Entities:
Keywords: Patient-reported outcome measures; Peripheral arterial disease; Psychometric; Systematic review; Validation
Mesh:
Year: 2016 PMID: 27881127 PMCID: PMC5121983 DOI: 10.1186/s12955-016-0563-y
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Criteria for considering eligibility of studies for inclusion in the review
| Inclusion criteria | Exclusion criteria | |
|---|---|---|
| Population | Defined population of English-speaking participants aged 18 years (adults) with PADa
| Undefined population or Non-English speaking adults with PAD |
| Interventions | No intervention or any intervention indicated for PAD | Intervention, not intended for the management of PAD |
| Outcomes | Original version of PROMs in English including | Original version of PROMs in English including |
| Study type | Validation studies of a relevant PROM addressing | Studies of linguistic validation of PROMs |
Abbreviations: EQ-5D EuroQoL-5D, PAD peripheral arterial disease, PROM patient-reported outcome measure, SF-6D 6-item shortened version of SF-36, SF-36 Medical Outcomes Study 36-item short form health survey, SG standard gamble, TTO time trade-off
aOther descriptions considered included peripheral vascular disease; peripheral obliterative arteriopathy; peripheral arterial occlusive disease
Appraisal criteria for assessing the psychometric properties of patient reported outcome measures
| Domain | Criteria |
|---|---|
| Test re-test reliability |
|
| Internal consistency |
|
| Content validity |
|
| Construct validity |
|
| Criterion validity |
|
| Responsiveness |
|
| Floor-ceiling effects | A floor or celling effect is considered if 15% of respondents are achieving the lowest or the highest score on the instrument, respectively [ |
| Acceptability | Acceptability is reflected by the completeness of the data supplied. 80% or more of the data should be complete [ |
Fig. 1Flow diagram of study selection here
Table of characteristics of included studies
| Author year, country | Reported PROM (s) | Clinical presentation (Sample size) (Ankle brachial index cut-off) | Age (years) | Gender (% males) | Timing of PROM (s) assessment | Concomitant treatment |
|---|---|---|---|---|---|---|
| Chetter 1997, UK [ | EQ-5D | Peripheral arterial disease | 68◊ | 61 | Baseline, week 1 | NR |
| (NR) | ||||||
| Chong 2002, UK [ | EQ-5D | Intermittent claudication | 71◊ | 61 | Baseline, week 2, month 3 | conservative medical treatment; percutaneous transluminal angioplasty |
| (≤0.9) | ||||||
| Coyne 2003, USA [ | EQ-5D | Peripheral arterial disease | 67 | 78 | Baseline, day 4, 7, 14 and 28 | NR |
| (<0.9, at rest) | ||||||
| Gulati 2009, UK [ | SF-36 | Peripheral arterial disease | 66◊ | 70 | Baseline; at week 2 | NR |
| (NR) | ||||||
| Izquierdo-Porrera 2005, USA [ | SF-36 | Intermittent claudication | 71 | 91 | Baseline, at week 1 | exercise rehabilitation |
| ( | ||||||
| Mazari 2010, UK [ | EQ-5D | Intermittent claudication | 70◊ | 60 | Baseline, at month 1, 3, 6, 12 | transluminal angioplasty, supervised exercise program, or combined treatment |
| McDermott 1998, UK [ | WIQ | Intermittent claudication | 71.4 | 57 | Baseline | NR |
| (≤0.9, at rest) | ||||||
| Mehta 2006b, UK [ | EQ-5D | Intermittent claudication | 70◊ | 54 | Baseline, at month 6 | Percutaneous transluminal angioplasty ( |
| (NR) | ||||||
| Morgan 2001, UK [ | SF-36 | Peripheral arterial disease | 67◊ | 62 | Baseline, at week 4 | general advice, medical treatment, angioplasty ( |
| (NR) | ||||||
| Regensteiner 1990, USA [ | WIQ | Intermittent claudication | 59 (exercise group); 64 (surgery group) 61 (control group) | NR | Baseline, at week 1, 6 and 12 | supervised exercise ( |
| (<0.90, at rest; < 0.85, after exercise) | ||||||
| Smith 2007, Australia [ | SF-36 AUSVIQOL | Intermittent claudication | 72.8 | 68 | Baseline, at month 1 | NR |
| (NR) | ||||||
| Spertus 2004, USA [ | WIQ | Peripheral arterial disease | 68 | 55 | Baseline; at week 2 and 8 | Peripheral revascularization |
| (NR) | ||||||
| Tew 2013c, UK [ | WIQ | Intermittent claudication | 65 | 81 | Baseline, within days 7 to 10 of first visit | NR |
| ( | ||||||
| (≤0.9, at rest) | ||||||
| Treat-Johnson 2012, USA [ | PADQOL | Peripheral arterial disease | 67.9 | 75 | Baseline; follow-up (not specified) | NR |
| (NR) |
Abbreviations: AUSVIQUOL Australian Vascular Quality of Life Index, EQ-5D EuroQoL-5D, IC intermittent claudication, ICQ Intermittent Claudication Questionnaire, M male, NR not reported, NHP Nottingham Health Profile, PAD peripheral arterial disease, PADQOL PAD Quality of Life Questionnaire, PAQ Peripheral Artery Questionnaire, POMS Profile of Mood States, SF-36 Medical Outcomes Study 36-item Short Form, SF-6D 6-item shortened version of SF-36, SF-8 8-item shortened version of SF-36, SIPic Sickness Impact Profile–Intermittent Claudication, VascuQoL King’s College Hospital’s Vascular Quality of Life instrument, WIQ Walking Impairment Questionnaire
◊Indicates median age, other values relate to reported mean ages
aData presented for sub-group of study population with PAD only
bStudy also reported the validation of English version of the Claudication Scale (CLAU-S)
cStudy also reported the validation of English version of the Estimation of Ambulatory Capacity by History-Questionnaire (EACH-Q)
Table of items, domains, response options, scoring and administration of included outcome measures
| Instrument (number of items) | Domains (number of levels) | Measure: Response options | Scoring | Mode of administration (reported completion time, min) |
|---|---|---|---|---|
| Generic PROMs | ||||
| SF-36 (36) [ | Vitality (4), physical functioning (10), bodily pain (2), general health perceptions (5), physical role functioning (4), emotional role functioning (3), social role functioning (2), mental health (5) | Likert scale: 2 to 5 | Each dimension is transformed to give a score of 0 to 100. Lower scores indicating greater disability | Self-completed (11 min) |
| EQ-5D (6) [ | Mobility (1), self-care (1), usual activities (1), pain/discomfort (1), and anxiety/depression (1); VAS | Likert scale: 3; VAS | Preference based, values range from 0 indicating death to 1 representing perfect health | Self-completed |
| SF-6D [ | Physical functioning (1), role limitation (1), social functioning (1), pain (1), mental health (1), and vitality (1) | Likert scale: 4 to 6 | Preference based 0 = dead to 1 = perfect health | Self-completed |
| SF-8 (8) [ | Vitality (1), physical functioning (1), bodily pain (1), general health perceptions (1), physical role functioning (1), emotional role functioning (1), social role functioning (1), mental health (1) | Likert scale: 5 | Each dimension is transformed to give a score of 0–100. Lower scores indicating greater disability | Self-completed (2.5 min) |
| NHP (38) [ | Physical mobility (8), pain (8), sleep (5), energy (3), emotional reactions (9), and social isolation (5) | Dichotomous | 0 (no health problems) to 100 (all the health problems) | Self-completed |
| POMS (65) [ | NR | Likert scale: 5 | NR | Self-completed |
| Condition-specific PROMs | ||||
| AUSVIQUOL (10) [ | General health perceptions (3), function, mobility and pain (5), psychosocial aspects (2) | Likert scale: 5 | Reponses are given points from 10 to 0 for each answer, these are summed to give a quality of life score ranging from 0 (poor) to 100 (excellent) | Interviewer or self-completed (3.27 min) |
| ICQ (16) [ | Health related quality of life (16) | Likert scale: 5 | Summing scores and transforming to a 0–100 scale | Self-completed (3.7 min) |
| PAQ (20) [ | Physical limitation (7), symptoms (4), quality of life (3), social function (3), treatment satisfaction (3) | Likert scale: 5 | 0–100 (lower scores indicating worse performance) | Self-completed |
| PADQOL (38) [ | Social relationships and interactions (9), self-concept and feelings (7), symptoms and limitations in physical functioning (8), fear and uncertainty (4), positive adaptation (7) | Likert scale :5 | Summed and transformed score 0 to 100% | Self-completed (5 to10 min) |
| SIPic (12) [ | Sickness related behaviour (12) | Number of items endorsed | 0 (best quality of life) to 12 (worst quality of life) | Self-completed |
| WIQ (14) [ | Symptom severity (8) | Likert scale: 5 | 0 (unable to do) to 4 (no difficulty) | Self-completed (6 min) |
| VascuQol (25) [ | Pain (4), activity (8), emotional (7), symptoms (4), and social (2) | Likert scale: 7 | 1 (the worst) to7 (the best possible) | Self-completed |
Abbreviations: AUSVIQUOL Australian Vascular Quality of Life Index, EQ-5D EuroQol, ICQ Intermittent Claudication Questionnaire, NR not reported, NHP Nottingham Health Profile, PAD peripheral arterial disease, PADQOL PAD Quality of Life Questionnaire, PAQ Peripheral Artery Questionnaire, POMS Profile of Mood States, SF-36 Medical Outcomes Study 36-item Short Form, SF-6D 6-item shortened version of SF-36, SF-8 8-item shortened version of SF-36, SIPic Sickness Impact Profile–Intermittent Claudication, VAS visual analogue scale, VascuQoL King’s College Hospital’s Vascular Quality of Life instrument, WIQ Walking Impairment Questionnaire
Summary of the psychometric properties of patient-reported outcome measures in patients with peripheral arterial disease
| Internal consistency | Test-retest | Content validity | Construct validity | Responsiveness | Floor/ ceiling | Acceptability | |
|---|---|---|---|---|---|---|---|
| Generic PROMs | |||||||
| EQ-5D | |||||||
| Chetter 1997 [ | 0 | ? | 0 | −/+ | −/+ | 0 | 0 |
| Chong 2002 [ | 0 | 0 | 0 | ? | −/+ | 0 | 0 |
| Coyne 2003 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| Mazari 2010 [ | 0 | 0 | 0 | + | −/+ | 0 | 0 |
| Mehta 2006 [ | 0 | 0 | 0 | ? | + | 0 | 0 |
| NHP | |||||||
| Chetter 1997 [ | 0 | ? | 0 | −/+ | + | −/+ | 0 |
| POMS | |||||||
| Treat-Jacobson 2012 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| SF-6D [ | 0 | 0 | 0 | −/+ | + | 0. | 0 |
| SF-8 | |||||||
| Gulati 2009 [ | 0 | ? | 0 | + | −/+ | 0 | 0 |
| SF-36 | |||||||
| Chetter 1997 [ | 0 | ? | 0 | −/+ | −/+ | −/+ | 0 |
| Chong 2002 [ | 0 | 0 | 0 | + | −/+ | 0 | 0 |
| Coyne 2003 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| Gulati 2009 [ | 0 | ? | 0 | + | −/+ | 0 | 0 |
| Izquierdo-Porrera 2005 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| Mazari 2010 [ | 0 | 0 | 0 | −/+ | + | 0 | 0 |
| Mehta 2006 [ | 0 | 0 | 0 | + | −/+ | 0 | 0 |
| Morgan 2001 [ | 0 | 0 | 0 | + | −/+ | 0 | 0 |
| Smith 2007 [ | − | + | 0 | −/+ | 0 | 0 | ? |
| Spertus 2003 [ | + | + | 0 | + | −/+ | 0 | 0 |
| Treat-Jacobson 2012 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| Condition-specific PROMs | |||||||
| AUSVIQUOL | |||||||
| Smith 2007 [ | + | + | 0 | −/+ | 0 | 0 | ? |
| ICQ | |||||||
| Chong 2002 [ | −/+ | + | + | −/+ | + | ? | + |
| PADQOL | |||||||
| Treat-Jacobson 2012 [ | + | 0 | + | −/+ | 0 | 0 | 0 |
| PAQ | |||||||
| Spertus 2003 [ | + | + | + | + | + | 0 | 0 |
| SIPic | |||||||
| Mehta 2006 [ | 0 | 0 | 0 | + | −/+ | 0 | 0 |
| WIQ | |||||||
| Chong 2002 [ | 0 | 0 | 0 | −/+ | −/+ | 0 | 0 |
| Coyne 2003 [ | −/+ | −/+ | 0 | + | 0 | 0 | 0 |
| Izquierdo-Porrera 2005 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| McDermott 1998 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| Regensteiner 1990 [ | 0 | ? | 0 | −/+ | + | 0 | 0 |
| Spertus 2003 [ | −/+ | + | 0 | + | −/+ | 0 | 0 |
| Tew 2013 [ | 0 | 0 | 0 | −/+ | 0 | 0 | + |
| Treat-Jacobson 2012 [ | 0 | 0 | 0 | −/+ | 0 | 0 | 0 |
| VascuQoL | |||||||
| Mazari 2010 [ | 0 | 0 | 0 | + | + | 0 | 0 |
| Mehta 2006 [ | 0 | 0 | 0 | + | −/+ | 0 | 0 |
| Morgan 2001 [ | + | + | + | + | + | 0 | 0 |
| Psychometric and operational criteria | |||||||
| 0 | Not reported (no evaluation completed) | ||||||
| - | Evidence not in favour | ||||||
| −/+ | Weak evidence in favour | ||||||
| + | Evidence in favour | ||||||
| ? | Methodology questionable | ||||||
| N.B. Blank criterion validity excluded from the table. | |||||||
NB Criterion validity recorded as zero across studies therefore results are not displayed
Abbreviations: AUSVIQUOL Australian Vascular Quality of Life Index, Q Questionnaire, EQ-5D EuroQol, ICQ Intermittent Claudication Questionnaire, NHP Nottingham Health Profile, PAD peripheral arterial disease, PADQOL PAD Quality of Life Questionnaire, PAQ Peripheral Artery Questionnaire, POMS Profile of Mood States, SF-36 Medical Outcomes Study 36-item Short Form, SF-6D 6-item shortened version of SF-36, SF-8 8-item shortened version of SF-36, SIPic Sickness Impact-Intermittent Claudication, VascuQoL King’s College Hospital’s Vascular Quality of Life instrument, WIQ Walking Impairment Questionnaire